文献速递儿童神经与发育行为儿童感染

利妥昔单抗治疗儿童神经系统自身免疫性疾病的有效性与安全性

[Effectiveness and safety of rituximab for children with autoimmune diseases of the nervous system].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2017-01-01

该双向性队列研究纳入38例难治性或复发性儿童神经系统自身免疫性疾病患者,给予利妥昔单抗治疗并随访。治疗后改良Rankin量表评分和年复发率均较治疗前显著下降(P<0.01),总有效率74%,常见不良反应为过敏和感染。结论认为利妥昔单抗对儿童难治性、复发性神经系统自身免疫性疾病有效且安全。

要点

  • 利妥昔单抗可显著改善儿童难治性神经系统自身免疫病的mRs评分和年复发率。
  • 38例患儿总有效率74%,多数获益,少数无效或加重。
  • 常见不良反应为过敏和感染,严重感染如卡氏肺囊虫肺炎少见。

核心结论

  • 利妥昔单抗治疗儿童难治性、复发性神经系统自身免疫性疾病有效且安全,尤其对视神经脊髓炎和重症肌无力。

研究设计与样本

  • 双向性队列研究,纳入2010年6月至2016年6月北京大学第一医院儿科38例经糖皮质激素或免疫球蛋白治疗无效或复发的住院患儿。
  • 患儿接受利妥昔单抗治疗并每3个月随访1次,采用改良Rankin量表(mRs)和年复发率评价疗效,监测B细胞并记录不良反应。
  • 38例中男15例、女23例,平均年龄(6±4)岁;多发性硬化4例,视神经脊髓炎5例,眼球阵挛肌阵挛综合征6例,重症肌无力9例,免疫性脑炎及其他14例。
  • 病程2~87个月,平均(21±19)个月;随访时间2~52个月。

主要发现

  • 治疗前mRs评分为3(3,4)分,年复发率2.56(1.80,4.75)次/年;治疗后mRs评分为0(0,2)分,年复发率0(0,0.17)次/年。
  • 治疗前后mRs评分和年复发率差异均有统计学意义(Z=-4.51、-4.71,P均<0.01)。
  • 38例中控制23例,显效2例,有效3例,无效1例,加重2例,因随访时间短不能确定疗效6例,因过敏反应退出治疗1例,总有效率74%。
  • 随访期间出现严重肺部卡氏肺囊虫感染1例,严重过敏反应导致放弃治疗1例。

关键数值与推荐

  • 疗效评价采用改良Rankin量表(mRs)和年复发率(次/年)。
  • 总有效率74%(排除6例不能确定疗效及1例因过敏退出者)。
  • 常见不良反应为过敏和感染;严重肺部卡氏肺囊虫感染1例。

临床怎么用

  • 对于经糖皮质激素或免疫球蛋白治疗无效或复发的儿童神经系统自身免疫性疾病,可考虑使用利妥昔单抗。
  • 治疗期间需监测B细胞并警惕过敏和感染等不良反应。

局限性

  • 样本量较小(38例),部分患者随访时间短,6例疗效不能确定。
  • 为双向性队列研究,非随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To assess the effectiveness and safety of rituximab in Chinese children with autoimmune diseases of the nervous system. Method: An ambispective cohort study enrolled patients with refractory and(or) relapse autoimmune diseases of nervous system from June 2010 to June 2016 in Peking University First Hospital.These patients failed to respond to steroids and(or)intravenous immunoglobulin (IVIG) were treated with rituximab and seen for follow-up visits once every 3 months.The effectiveness was assessed by modified Rankin scale (mRs) and the annualized relapse rate.B cell was repeatedly counted after the treatment.Side effects attributed to rituximab were recorded.Paired rank test and chi-square test were used to compare the mRs score and the recurrence rate (time/year) before and after the treatment. Result: A total of 38 patients (15 males and 23 females) with mean age of (6±4) years were treated with rituximab.Among those patients, 4 cases were in multiple sclerosis, 5 in neuromyelitis optica, 6 in opsoclonus myoclonus syndrome, 9 in myasthenia gravis, and 14 in autoimmune encephalitis and other nervous system autoimmune diseases.The course of the disease before rituximab treatment was from two months to 7.25 years, with the average of (21±19) months.The patients had been followed up for 2-52 months. The mRs score and recurrence rate of 38 patients before receiving rituximab was 3 points (3, 4) and 2.56 (1.80, 4.75) times per year, respectively, while patients after receiving rituximab were mRs score of 0 (0, 2) and had a recurrence rate of 0 (0, 0.17) per year.There was statistical difference before and after treatment (Z=-4.51 and -4.71, P<0.01). Rituximab had a definite benefit in 23 patients, probable benefit in 2 patients, possible benefit in 3 patients, no benefit in one patient, and the disease worsened in 2 patients.Therefore the total effective rate was 74%, except for 6 undetermined cases because of the short follow-up time, and one patient withdrew from the study due to allergic reaction.During the follow-up, only one patient with severe allergy gave up the rituximab treatment. And only one patient was found severe infection with Pneumocystis carinii pneumonia. Conclusion: Rituximab is an effective and safe treatment strategy for patients with refractory and relapse autoimmune diseases of CNS, especially in neuromyelitis optica and myasthenia gravis.The adverse events including infection and allergy during infusion are not common. 目的: 评价利妥昔单抗在儿童神经系统自身免疫性疾病治疗中的效果及安全性。 方法: 采用双向性队列研究,对2010年6月至2016年6月于北京大学第一医院儿科诊断为神经系统自身免疫性疾病,经糖皮质激素或免疫球蛋白治疗无效或复发的住院患儿给予利妥昔单抗治疗,并每3个月随访1次,应用改良Rankin量表及年复发率进行疗效评价;行B细胞数值监测;观察药物的不良反应。采用配对秩和检验对每种疾病治疗前后应用改良Rankin量表评分及复发率(次/年)进行比较。 结果: 应用利妥昔单抗治疗的患儿共38例,其中男15例、女23例,平均年龄(6±4)岁,其中多发性硬化4例,视神经脊髓炎5例,眼球阵挛肌阵挛综合征6例,重症肌无力9例,免疫性脑炎及其他神经系统免疫性疾病14例。患儿病程2~87个月,平均(21±19)个月,随访时间2~52个月。38例患儿使用利妥昔单抗前改良Rankin量表评分3(3,4)分,年复发率2.56(1.8,4.75)次/年,使用利妥昔单抗后改良Rankin量表评分0(0,2)分,年复发率0(0,0.17)次/年,二者治疗前后差异均有统计学意义(Z=-4.51、-4.71,P均<0.01)。38例患儿中控制23例,显效2例,有效3例,无效1例,加重2例,因随访时间短不能确定疗效6例,因过敏反应退出治疗1例,总有效率74%。出现严重的肺部卡氏肺囊虫感染1例。 结论: 利妥昔单抗治疗儿童难治性、复发性神经系统自身免疫性疾病尤其是视神经脊髓炎和重症肌无力安全性好,常见不良反应为过敏和感染。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Fu Z, Bao XH, Wu Y, et al. [Effectiveness and safety of rituximab for children with autoimmune diseases of the nervous system]. Zhonghua Er Ke Za Zhi. 2017. PMID: 28881516. doi:10.3760/cma.j.issn.0578-1310.2017.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。